Subsequently, regorafenib, an oral multikinase inhibitor targeting angiogenic (VEGFR1, VEGFR2, and tyrosine kinase with Ig and epidermal growth factor homology domain-2), stromal (platelet-derived growth factor receptor beta [PDGFRβ]), and oncogenic (rapidly accelerated fibrosarcoma [RAF], rearranged during transfection [RET], and KIT receptor tyrosine kinases, showed longer survival than placebo during salvage-line treatment of AGC outside of China [12,13]. This evidence concerns the gene PDGFRB and fibrosarcoma.